These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 38102140)
1. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57 Pomella S; Cassandri M; D'Archivio L; Porrazzo A; Cossetti C; Phelps D; Perrone C; Pezzella M; Cardinale A; Wachtel M; Aloisi S; Milewski D; Colletti M; Sreenivas P; Walters ZS; Barillari G; Di Giannatale A; Milano GM; De Stefanis C; Alaggio R; Rodriguez-Rodriguez S; Carlesso N; Vakoc CR; Velardi E; Schafer BW; Guccione E; Gatz SA; Wasti A; Yohe M; Ignatius M; Quintarelli C; Shipley J; Miele L; Khan J; Houghton PJ; Marampon F; Gryder BE; De Angelis B; Locatelli F; Rota R Nat Commun; 2023 Dec; 14(1):8373. PubMed ID: 38102140 [TBL] [Abstract][Full Text] [Related]
2. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma. Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019 [TBL] [Abstract][Full Text] [Related]
3. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma. Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785 [TBL] [Abstract][Full Text] [Related]
4. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416 [TBL] [Abstract][Full Text] [Related]
5. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678 [TBL] [Abstract][Full Text] [Related]
6. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014 [TBL] [Abstract][Full Text] [Related]
7. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma. Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669 [TBL] [Abstract][Full Text] [Related]
8. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma. Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042 [TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells. Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328 [TBL] [Abstract][Full Text] [Related]
12. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma. Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971 [TBL] [Abstract][Full Text] [Related]
13. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation. Perrone C; Pomella S; Cassandri M; Pezzella M; Giuliani S; Gasperi T; Porrazzo A; Alisi A; Pastore A; Codenotti S; Fanzani A; Barillari G; Conti LA; De Angelis B; Quintarelli C; Mariottini P; Locatelli F; Marampon F; Rota R; Cervelli M Front Cell Dev Biol; 2023; 11():1061570. PubMed ID: 36755974 [TBL] [Abstract][Full Text] [Related]
14. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
16. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway. Hernandez KC; Shah AM; Lopez VA; Tagliabracci VS; Chen K; Xu L; Bassel-Duby R; Olson EN; Liu N Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2315925121. PubMed ID: 38227654 [TBL] [Abstract][Full Text] [Related]
17. Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. Li S; Chen K; Zhang Y; Barnes SD; Jaichander P; Zheng Y; Hassan M; Malladi VS; Skapek SX; Xu L; Bassel-Duby R; Olson EN; Liu N Genes Dev; 2019 Jun; 33(11-12):626-640. PubMed ID: 30975722 [TBL] [Abstract][Full Text] [Related]